ASCO issued a new update on adjuvant chemotherapy recommendations in patients diagnosed with early breast, the new updated recommendations can be summarized as follow,

Adding 6 months of Capcetabine for patients who received neoadjuvant chemotherapy and was found to have residual disease at surgery for details click here.

For high risk Her2 positive patient-targeted therapy with trastuzumab and pertuzumab-based combination for 12 months.

Consideration of adding Neratinib for high-risk Her2 positive patients for details click here.

For further details click here.